Compared with the EGFR-TKIs only therapy, the therapy of angiogenesis inhibitors with EGFR-TKIs together prolonged the PFS of advanced EGFR-mutation NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.